Abstracts Archive - Page 1247 of 2425 - ACR Meeting Abstracts

Abstract Number: 622 • 2017 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Minimal Disease Activity (MDA) and Remission Related to Disease Activity Index for Psoriatic Arthritis (DAPSA): 2-Year Results from a Phase 3 Study
Laura C Coates¹, Peter Nash², Tore Kvien³, Laure Gossec⁴, Philip J Mease⁵, Lawrence Rasouliyan⁶, Luminita Pricop⁷, Steffen Jugl⁸, Kunal Gandhi⁷, Corine Gaillez⁸ and Josef S. Smolen⁹, ¹University of Oxford, Leeds, Great Britain, ²University of Queensland, Brisbane, Australia, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴UPMC, University Paris 06, Pitié-Salpétrière Hospital, Paris, France, ⁵Swedish Medical Center and University of Washington, Seattle, WA, ⁶RTI Health Solutions, Barcelona, Spain, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria
Background/Purpose: Very low disease activity (VLDA) or remission (REM) and alternatively, minimal disease activity (MDA) or low disease activity (LDA) are optimal targets to be…
Abstract Number: 623 • 2017 ACR/ARHP Annual Meeting
Tofacitinib Improves Composite Endpoint Measures of Disease in Patients with Psoriatic Arthritis
Philip S. Helliwell¹, Laura C Coates¹, Oliver FitzGerald², Peter Nash³, Enrique R Soriano⁴, M. Elaine Husni⁵, Ming-Ann Hsu⁶, Keith S Kanik⁶, Thijs Hendrikx⁷, Joseph Wu⁶ and Elizabeth Kudlacz⁶, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²ASRI, Dublin, Ireland, Dublin, Ireland, ³Department of Medicine, University of Queensland, St Lucia, Brisbane, Australia, ⁴Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁵Cleveland Clinic Lerner Research Institute, Cleveland, OH, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor under investigation for the treatment of psoriatic arthritis (PsA). PsA is a heterogeneous disease and composite endpoints…
Abstract Number: 624 • 2017 ACR/ARHP Annual Meeting
Ixekizumab Provides Sustained Improvement in Signs and Symptoms in Patients with Active Psoriatic Arthritis: Two Year Results from a Phase 3 Trial
Philip S. Helliwell¹, Eric Lespessailles², Catherine Shuler³, Lotus Mallbris³, Janelle Erickson³ and Roy Fleischmann⁴, ¹St. Luke's Hospital and University of Leeds, Bradford, United Kingdom, ²University Orleans, Orleans, France, ³Eli Lilly and Company, Indianapolis, IN, ⁴Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Ixekizumab (IXE) is a high affinity monoclonal antibody that selectively targets IL-17A. In the SPIRIT-P1 phase 3 study (NCT01695239), IXE was superior to placebo…
Abstract Number: 625 • 2017 ACR/ARHP Annual Meeting
Rapid Onset of Efficacy in Patients with Active Psoriatic Arthritis Treated with Ixekizumab: A Pooled Analysis of Data from Two Phase III Clinical Trials
Atul A. Deodhar¹, Kim A. Papp², Catherine Shuler³, So Young Park³ and Tore K. Kvien⁴, ¹Oregon Health & Science University, Portland, OR, ²K Papp Clinical Research and Probity Medical Research Inc, Waterloo, ON, Canada, ³Eli Lilly and Company, Indianapolis, IN, ⁴Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Rapid onset of clinical improvement is an important attribute of treatment success for patients with PsA. These analyses evaluate the speed of onset of…
Abstract Number: 626 • 2017 ACR/ARHP Annual Meeting
Radiographic Progression of Structural Joint Damage in Patients with Active Psoriatic Arthritis Treated with Ixekizumab over 52 Weeks
Désirée van der Heijde¹, Masato Okada², Chin H. Lee³, Catherine Shuler³, Suchitrita Rathmann³, Chen-Yen Lin³ and Philip J Mease⁴, ¹Leiden University Medical Center, Leiden, Netherlands, ²Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ³Eli Lilly and Company, Indianapolis, IN, ⁴Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose: Ixekizumab (IXE), an anti-interleukin-17A monoclonal antibody, was shown to be superior to placebo (PBO) in clinical responses and inhibiting the progression of structural joint…
Abstract Number: 627 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Apremilast through 104 Weeks in Subjects with Moderate to Severe Psoriasis Randomized to Placebo, Apremilast, or Etanercept Who Continued on or Switched to Apremilast after Week 16 in a Phase 3b Study
Kristian Reich¹, Mark Goodfield², Lawrence Green³, Kristine Nograles⁴, Rongdean Chen⁴, Eugenia Levi⁴ and Richard G.B. Langley⁵, ¹Dermatologikum Hamburg, Hamburg, Germany, ²Leeds General Infirmary, Leeds, United Kingdom, ³George Washington University School of Medicine, Washington, DC, WA, ⁴Celgene Corporation, Summit, NJ, ⁵Dalhousie University, Halifax, NS, Canada
Background/Purpose: Many subjects (sbj) with chronic plaque psoriasis exhibit nail and scalp involvement that can markedly affect quality of life and be difficult to treat.…
Abstract Number: 628 • 2017 ACR/ARHP Annual Meeting
Integrated Efficacy Results from Two Phase 3 Trials of Ixekizumab for the Treatment of Psoriatic Arthritis
Bernard Combe¹, Peter Nash², David Adams³, Lisa Kerr³ and Olivier Benichou³, ¹Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, ²University of Queensland, Brisbane, Australia, ³Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Ixekizumab (IXE) is a high-affinity monoclonal antibody that selectively targets interleukin-17A. Here, we present integrated efficacy data at Week 24 from two phase 3…
Abstract Number: 629 • 2017 ACR/ARHP Annual Meeting
Is Earlier Golimumab Treatment Initiation in Psa and As Patients Associated with Improved Outcomes?
Suneil Kapur¹, Proton Rahman², Michelle Teo³, Jodie Reis⁴, Rajwinder Dhillon⁵, Pauline Boulos⁶, Raman Rai⁷, Regan Arendse⁸, Julie Vaillancourt⁹, Emmanouil Rampakakis⁹, Allen J Lehman¹⁰, Francois Nantel¹¹ and Brendan Osborne¹¹, ¹University of Ottawa, 139 Greenbank Rd, Suite 203, ON, Canada, ²Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, ³Balfour Medical Clinic, Penticton, BC, Canada, ⁴University of Saskatchewan, Saskatoon, SK, Canada, ⁵Private Practice, Niagara Falls, ON, Canada, ⁶Private Practice, Dundas, ON, Canada, ⁷Private Practice, Hamilton, ON, Canada, ⁸University of Saskatchewan, Saskatoon, ON, Canada, ⁹JSS Medical Research, Montreal, QC, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Previous studies have suggested that treating patients earlier with biologics could improve disease outcomes. The aim of this analysis was to assess the impact…
Abstract Number: 630 • 2017 ACR/ARHP Annual Meeting
Effects of Intravenous Golimumab, an Anti-Tnfα Monoclonal Antibody, on Mental and Physical Functioning and Health-Related Quality of Life in Active Psoriatic Arthritis: 24-Week Results of a Phase 3 Trial
M. Elaine Husni¹, Arthur Kavanaugh², Eric K. H. Chan³, Nan Li⁴, Steven Peterson⁴, Elizabeth C. Hsia⁵, Lilianne Kim⁴, Kim Hung Lo⁴ and Diane D. Harrison⁴, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Medicine, University of California, San Diego, La Jolla, CA, ³Janssen Global Services, LLC, Raritan, NJ, ⁴Janssen Research & Development, LLC, Spring House, PA, ⁵Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA
Background/Purpose: To evaluate physical and mental health functioning, health state, and health-related quality of life (HRQoL) in patients with active psoriatic arthritis (PsA) treated with…
Abstract Number: 631 • 2017 ACR/ARHP Annual Meeting
Predictors of Long-Term Retention of Methotrexate and Other Dmards with Golimumab in Rheumatoid Arthritis and Psoriatic Arthritis: An Analysis from a Prospective, Observational Registry
Derek Haaland¹, Anna Jaroszynska², B Haraoui³, Suneil Kapur⁴, Jacqueline Stewart⁵, Wojciech Olsynzynski⁶, Keltie Anderson⁷, Raman Rai⁸, Michael Starr⁹, Alexander Tsoukas¹⁰, Eliofotisti Psaradellis¹¹, Emmanouil Rampakakis¹¹, Cathy Tkaczyk¹², Allen J Lehman¹³, Francois Nantel¹² and Brendan Osborne¹², ¹Rheumatology, Clinical Immunology & Allergy, McMaster University, Barrie, ON, Canada, ²Private practice, Burlington, ON, Canada, ³Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ⁴University of Ottawa, 139 Greenbank Rd, Suite 203, ON, Canada, ⁵Penticton Regional Hospital, Penticton, BC, Canada, ⁶University of Saskatchewan, Saskatoon, ON, Canada, ⁷University of Saskatchewan, Saskatoon, SK, Canada, ⁸Private Practice, Hamilton, ON, Canada, ⁹Rheumatology, McGill University, Pointe-Claire,, QC, Canada, ¹⁰McGill University, Montreal, QC, Canada, ¹¹JSS Medical Research, Montreal, QC, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Janssen Inc., Toronto, ON, Canada
Background/Purpose: Previous studies have suggested that concomitant methotrexate therapy may increase the efficacy of biologic treatments. A scarcity of data exists on the benefits of…
Abstract Number: 632 • 2017 ACR/ARHP Annual Meeting
Long-Term Golimumab Retention Rate in Patients with Psoriatic Arthritis. Is Concomitant DMARD Important?
Belen Serrano¹, Carlos M Gonzalez², Roberto González³, Juan Gabriel Ovalles-Bonilla⁴, Juan Carlos Nieto², Julia Martínez-Barrio⁵, Iustina Janta², Larissa Valor³, Indalecio Monteagudo² and Francisco Javier López Longo⁶, ¹Rheumatology, Hospital General Universitario Gregorio Marañón, Genoa, Italy, ²Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Rheumatology, Hospital general Universitario Gregorio Marañón, Madrid, Spain, ⁴Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain, ⁵Servicio de Reumatologia, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁶Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
Background/Purpose: The efficacy of Golimumab (GLM) treatment in psoriatic arthritis (PsA) patients has been widely documented. The aim of this study was to analyze the…
Abstract Number: 633 • 2017 ACR/ARHP Annual Meeting
Improvement of Joint Inflammation As Assessed By MRI and Power Doppler Ultrasound (PDUS) in an Open Label Study in Patients with Active Psoriatic Arthritis Treated with Secukinumab.
Eleni Kampylafka¹, Isabelle Oliveira¹, Christina Linz², Veronika Lerchen¹, Matthias Englbrecht¹, Michael Sticherling³, Arnd Kleyer¹, Juergen Rech¹, Georg Schett¹ and Axel J. Hueber¹, ¹Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany, ²Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, e, Germany, ³Department of Dermatology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany
Background/Purpose: Secukinumab, an anti-interleukin 17A monoclonal antibody, showed significant improvement of signs and symptoms of psoriatic arthritis (PsA) in phase 3 studies. Available studies used…
Abstract Number: 634 • 2017 ACR/ARHP Annual Meeting
International League of Associations for Rheumatology. Systematic Review of the Literature to Inform Treatment Recommendations for Psoriatic Arthritis in Resource-Poor Countries
Musaab Elmamoun¹, Maria Eraso², Laura C Coates³, Ajesh Maharaj⁴, Vinod Chandran⁵, Ahmed Abogamal⁶, Valderilio F Azevedo⁷, Wilson Bautista-Molano⁸, Alex G. Ortega⁹, Jorge Medina-Rosas^10,11, Fabian Hernandez^12,13, Adma Lima¹⁴, Uyi Ima-Edomwonyi¹⁵, Adeola Ajibade¹⁶, Tarun Narang¹⁷, Olusola Ayanlowo¹⁸, Claudia Goldenstein-Schainberg¹⁹, Roberto Ranza^{20,21,22,23,24,25}, Girish M Mody²⁶, Sueli Carneiro^27,28, Aman Sharma²⁹, Oscar Vega-Hinojosa³⁰, Luis E. Vega³¹, Adewale O Adebajo³² and Sergio Toloza³³, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Tornoto, ON, Canada, ³Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences,, Oxford, United Kingdom, ⁴Nelson R. Mandela School of Medicine, University of KwaZulu Natal, Durban, South Africa, ⁵Medicine, Krembil Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁶Al-Azhar University, Cairo, Egypt, ⁷Adjunct Professor of Rheumatology, Federal University of Paraná; Brazil, Curitiba, Brazil, ⁸School of Medicine, Universidad Militar Nueva Granada and Rheumatology Department Hospital Militar. Colombia, Bogotá, Colombia, ⁹Virginia Commonwealth University, Richmond, VA, ¹⁰Rheumatology, Universidad de la Sabana, Bogota, Colombia, ¹¹Universidad del Valle, Cali, Colombia, ¹²Universidad del Cauca, Popayan, Colombia, ¹³Universidad de Caldas, Pereira, Colombia, ¹⁴Federação Universidade Regional de Blumenau, Blumenau, Brazil, ¹⁵Internal Medicine, Lagos University Teaching Hospital, Surulere, Nigeria, ¹⁶Obafemi Awolowo University Teaching Hospitals Complex Osun state, Nigeria., Osogbo, Nigeria, ¹⁷Postgraduate Institute of Medical Education and Research, Chandigarh, India, ¹⁸Lagos University Teaching Hospital, Lagos, Nigeria, ¹⁹Universidade de São Paulo, São Paulo, Brazil, ²⁰on behalf of the BiobadaBrasil study group, Sociedade Brasileira de Reumatologia, Uberlandia, Brazil, ²¹Rua Otavio Rodrigues DaCunha, Uberlandia MG, Brazil, ²²Servicio de Reumatología, Universidade Federal de Uberlandia, Uberlandia, Brazil, ²³Reumatologia, Reumatologia, Universidade Federal de Uberlandia, Uberlandia, Brazil, ²⁴Matematica, Matematica, Universidade Federal de Uberlandia, Uberlandia, Brazil, ²⁵Universidade Federal de Uberlandia, Uberlandia MG, Brazil, ²⁶Dept of Rheumatology, University of Kwa Zulu-Natal, Durban, South Africa, ²⁷Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ²⁸University of São Paulo, Sao Paulo, Brazil, ²⁹Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ³⁰Clínica Reumacenter,, Juliaca, Peru, ³¹Hospita Central Fuerza Aerea Perú, Lima, Peru, ³²University of Sheffield, Sheffield, United Kingdom, ³³Rheumatology, Hospital San Juan Batista, Catamarca, Argentina, Catamarca, Argentina
Background/Purpose: Psoriatic Arthritis (PsA) is a heterogeneous disease which makes management of PsA a challenge. European League Against Rheumatism (EULAR) and the Group for Research…
Abstract Number: 635 • 2017 ACR/ARHP Annual Meeting
Short-Term Efficacy and Safety of New Biological Agents Targeting the IL-6, IL-12/23 and IL-17 Pathways for Active Psoriatic Arthritis: A Network Meta-Analysis of Randomised Controlled Trials
Dongze Wu, Jiang Yue and Lai-Shan Tam, Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: According to EULAR recommendations, in patients with peripheral arthritis and an inadequate response to at least one conventional synthetic DMARD, biologic DMARDs targeting IL-12/23,…
Abstract Number: 636 • 2017 ACR/ARHP Annual Meeting
Effect of Adding MTX to TNF Inhibitors on Joint Severity Indices and Skin Scores in Psoriatic Arthritis: A Post-Hoc Meta-Analysis of Randomized, Controlled Trials
Rochelle Castillo¹, Khushboo Sheth² and Santhanam Lakshminarayanan³, ¹University of Connecticut, Farmington, CT, ²Rheumatology, Stanford University, Palo Alto, CA, ³Division of Rheumatology, University of Connecticut Health Center, Farmington, CT
Background/Purpose: Co-medication of MTX with TNF inhibitors (TNFi) has proven superior to TNFi monotherapy in improving clinical outcomes in patients with RA. Whether this holds…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].